Candel Therapeutics, Inc. CADL

Updated: 10 Aug 2026

NASDAQ | Biotech | Cancer immunotherapy

No signal published yet

We already track Candel Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Candel Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Cancer immunotherapy
We're already tracking Candel Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On August 3, 2026, Candel Therapeutics announced that clinical data from its Phase 3 trial of aglatimagene besadenovec in localized prostate cancer was accepted for presentation at the ASTRO 2026 Annual Meeting. In June 2026, the company initiated the pivotal Phase 3 AURORA trial evaluating the same candidate in advanced non-small cell lung cancer.

What Firelda Watch includes for Candel Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Candel Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Moderna, Inc.
MRNA
HOLD
AstraZeneca PLC
AZN
HOLD
Calliditas Therapeutics
CALT
NEUTRAL
Ionis Pharmaceuticals, Inc.
IONS
HOLD
Exelixis, Inc.
EXEL
HOLD

Biotech

More companies in this sector

Want to follow Candel Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Candel Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Candel Therapeutics, Inc. CADL
Candel Therapeutics — follow and we'll monitor it
Follow Candel Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.